345 related articles for article (PubMed ID: 30053818)
1. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.
Su X; Kong Y; Peng DQ
Lipids Health Dis; 2018 Jul; 17(1):174. PubMed ID: 30053818
[TBL] [Abstract][Full Text] [Related]
2. The role of apolipoprotein A5 in obesity and the metabolic syndrome.
Zheng XY; Zhao SP; Yan H
Biol Rev Camb Philos Soc; 2013 May; 88(2):490-8. PubMed ID: 23279260
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein A5 regulates intracellular triglyceride metabolism in adipocytes.
Zheng XY; Yu BL; Xie YF; Zhao SP; Wu CL
Mol Med Rep; 2017 Nov; 16(5):6771-6779. PubMed ID: 28901468
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A5 internalized by human adipocytes modulates cellular triglyceride content.
Zheng XY; Zhao SP; Yu BL; Wu CL; Liu L
Biol Chem; 2012 Mar; 393(3):161-7. PubMed ID: 22718631
[TBL] [Abstract][Full Text] [Related]
5. New Insights into Apolipoprotein A5 and the Modulation of Human Adipose-derived Mesenchymal Stem Cells Adipogenesis.
Su X; Weng S; Peng D
Curr Mol Med; 2020; 20(2):144-156. PubMed ID: 31560287
[TBL] [Abstract][Full Text] [Related]
6. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
[TBL] [Abstract][Full Text] [Related]
7. The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.
Garelnabi M; Lor K; Jin J; Chai F; Santanam N
Clin Biochem; 2013 Jan; 46(1-2):12-9. PubMed ID: 23000317
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
Forte TM; Ryan RO
Curr Drug Targets; 2015; 16(12):1274-80. PubMed ID: 26028042
[TBL] [Abstract][Full Text] [Related]
9. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
Jakel H; Nowak M; Helleboid-Chapman A; Fruchart-Najib J; Fruchart JC
Ann Med; 2006; 38(1):2-10. PubMed ID: 16448983
[TBL] [Abstract][Full Text] [Related]
10. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway.
Li R; Chen LZ; Zhao W; Zhao SP; Huang XS
Biochem Biophys Res Commun; 2016 Sep; 478(3):1173-8. PubMed ID: 27544029
[TBL] [Abstract][Full Text] [Related]
11. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V.
Bertoccini L; Sentinelli F; Incani M; Bailetti D; Cimini FA; Barchetta I; Cavallo MG; Cossu E; Lenzi A; Loche S; Baroni MG
Lipids Health Dis; 2017 Sep; 16(1):179. PubMed ID: 28927406
[TBL] [Abstract][Full Text] [Related]
12. The exchangeable apolipoproteins in lipid metabolism and obesity.
Su X; Peng D
Clin Chim Acta; 2020 Apr; 503():128-135. PubMed ID: 31981585
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.
Hubacek JA
Gene; 2016 Oct; 592(1):193-199. PubMed ID: 27496343
[TBL] [Abstract][Full Text] [Related]
14. Association of apolipoprotein A5 gene variants with metabolic syndrome in Tunisian population.
Kefi R; Hechmi M; Dallali H; Elouej S; Jmel H; Halima YB; Nagara M; Chargui M; Fadhel SB; Romdhane S; Kamoun I; Turki Z; Abid A; Bahri S; Bahlous A; Gomis R; Baraket A; Grigorescu F; Normand C; Jamoussi H; Abdelhak S
Ann Endocrinol (Paris); 2017 Jul; 78(3):146-155. PubMed ID: 28624160
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.
Ibi D; Boot M; Dollé MET; Jukema JW; Rosendaal FR; Christodoulides C; Neville MJ; Koivula R; Rensen PCN; Karpe F; Noordam R; Willems van Dijk K
J Lipid Res; 2022 May; 63(5):100193. PubMed ID: 35278410
[TBL] [Abstract][Full Text] [Related]
16. Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.
Dai W; Zhang Z; Yao C; Zhao S
Lipids Health Dis; 2019 Dec; 18(1):220. PubMed ID: 31836003
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein A5, a unique modulator of fasting and postprandial triglycerides.
May-Zhang L; Liu M; Black D; Tso P
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Sep; 1867(9):159185. PubMed ID: 35644522
[TBL] [Abstract][Full Text] [Related]
18. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway.
Zhao SP; Li R; Dai W; Yu BL; Chen LZ; Huang XS
PLoS One; 2017; 12(9):e0184949. PubMed ID: 28934253
[TBL] [Abstract][Full Text] [Related]
19. Common functional variants of APOA5 and GCKR accumulate gradually in association with triglyceride increase in metabolic syndrome patients.
Hadarits F; Kisfali P; Mohás M; Maász A; Duga B; Janicsek I; Wittmann I; Melegh B
Mol Biol Rep; 2012 Feb; 39(2):1949-55. PubMed ID: 21643755
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin.
Smith CE; Tucker KL; Lai CQ; Parnell LD; Lee YC; Ordovás JM
Obesity (Silver Spring); 2010 Feb; 18(2):327-32. PubMed ID: 19629056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
